Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Ionis Pharmaceuticals executive Shannon L. Devers sold 3,977 shares of common stock on January 22, 2026 under a pre-arranged Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $81.3403 per share, with individual trades executed between $81.33 and $81.37. After this transaction, Devers beneficially owns 22,541 shares of Ionis Pharmaceuticals common stock in direct form.
An affiliate of IONS filed an amended notice of proposed sales of the issuer’s common stock under Rule 144. The filing covers a planned sale of 3,977 shares of common stock through broker Stifel Nicolaus & Company Inc., with an aggregate market value of $323,490.00, to be sold on or about 01/22/2026 on the Nasdaq market. These shares were acquired as restricted stock units from the issuer on 01/13/2026 as equity compensation, with payment dated 01/07/2026. The notice also lists prior sales in the last three months by Shannon Devers totaling several tranches of common stock, each with disclosed dates, amounts, and gross proceeds.
A shareholder has filed a notice of proposed sale of 3,977 shares of common stock through broker Stifel Nicolaus & Company on or about 01/22/2026, with the shares listed on Nasdaq. These shares were acquired on 01/13/2026 as restricted stock units from the issuer, with equity compensation recorded on 01/07/2026. The filing also notes that the same shareholder sold 44,199 shares of common stock on 01/07/2026 for gross proceeds of $3,756,915.00 and 16,777 shares on 11/25/2025 for gross proceeds of $1,342,160.00. The shareholder represents that they are not aware of any undisclosed material adverse information about the issuer’s operations.
Ionis Pharmaceuticals shareholder has filed a notice of proposed sale under Rule 144 for 1,171 shares of common stock, with an aggregate market value of $93,680.00. The shares are to be sold through Morgan Stanley Smith Barney on or about 01/16/2026 on the NASDAQ exchange.
The securities were acquired on 01/15/2026 as RSUs granted under the 2011 Equity Incentive Plan, treated as compensation from Ionis Pharmaceuticals. The filing notes that total common shares outstanding are 161,137,930, providing context for the size of this planned sale relative to the company’s equity base.
Ionis Pharmaceuticals director Michael J. Yang reported the vesting of restricted stock units and corresponding receipt of common shares. On 01/15/2026, 1,930 Restricted Stock Units were converted at an exercise price of $0.0 into 1,930 shares of Ionis common stock, reflecting the scheduled vesting of an equity award. Following these transactions, Yang beneficially owned 7,150 Restricted Stock Units and 7,940 shares of common stock, all held directly. The filing notes that each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock or its cash equivalent, and that these units vest in three equal annual installments.
Ionis Pharmaceuticals EVP Research Eric Swayze reported equity award activity and related stock sales. On January 15, 2026, restricted stock units vested, resulting in the acquisition of 21,366 shares of common stock at $0.0 per share, after which he held 51,819 shares directly. On January 16, 2026, he sold 9,884 shares of common stock at a weighted average price of $75.34 in an automatic sale to cover tax withholding, leaving 41,935 shares held directly. An account for his son held 318 shares after a sale of 49 shares.
He received a grant of 25,800 performance restricted stock units, representing the maximum earnable based on a three-year total shareholder return performance period, and 9,675 additional restricted stock units. His son was granted 225 restricted stock units. Each unit represents a contingent right to one share of Ionis common stock or its cash value, generally vesting in four equal annual installments.
Ionis Pharmaceuticals executive Eugene Schneider, EVP and Chief Clinical Development Officer, reported a mix of stock grants, vesting, and a sale. On 01/15/2026, 21,685 restricted stock units vested and were converted into common shares at an exercise price of $0.0, increasing his directly held common stock to 73,192 shares.
On the same date, he received a grant of 25,800 Performance Restricted Stock Units (PRSUs), representing the maximum 200% of target that may be earned after a three-year performance period based on relative total shareholder return, and a separate grant of 9,675 time-based RSUs that vest in four equal annual installments. On 01/16/2026, 9,302 common shares were sold at a weighted average price of $75.59 in an automatic sale to cover tax withholding obligations under the company’s equity plan, leaving him with 63,890 common shares directly owned, along with derivative holdings of PRSUs and RSUs.
Ionis Pharmaceuticals executive Patrick R. O'Neil, EVP, CLO & General Counsel, reported several equity transactions in Ionis common stock and equity awards.
On 01/15/2026, 21,473 shares of common stock were acquired at $0.0 upon vesting and release of Restricted Stock Units, increasing his directly held common stock to 75,362 shares. The same day, derivative positions changed as 25,800 Performance Restricted Stock Units were granted at $0.0, representing the maximum that may be earned after a three-year performance period tied to relative total shareholder return, and 9,675 additional Restricted Stock Units were granted.
On 01/16/2026, O'Neil sold 9,191 shares of common stock at a weighted average price of $75.84 in an automatic sale to cover tax withholding obligations under the company’s equity plan, leaving 66,171 common shares directly owned.
Ionis Pharmaceuticals Chief Executive Officer and director Brett P. Monia reported multiple equity award transactions and a related share sale. On January 15, 2026, 89,145 shares of common stock were acquired at $0.0 per share through the vesting and release of previously granted restricted stock units, increasing his directly held common stock to 268,717 shares. On the same day, he received 113,880 Performance Restricted Stock Units (PRSUs), representing the maximum earnable amount based on a three-year performance period, and 42,705 additional restricted stock units under the company’s equity incentive plan.
On January 16, 2026, Monia sold 44,034 common shares at a weighted average price of $74.82 per share in an automatic sale to cover required tax withholding obligations tied to the RSU vesting. Following these transactions, he directly beneficially owned 224,683 shares of common stock, alongside substantial outstanding PRSU and RSU awards that may convert into shares or cash in the future based on vesting and performance conditions.
Ionis Pharmaceuticals executive Holly Kordasiewicz reported a stock option grant under the company’s equity incentive plan. On 01/02/2026, she received a non-qualified stock option to purchase 7,500 shares of Ionis Pharmaceuticals common stock at an exercise price of $79.67 per share.
According to the filing, none of these options were exercisable on the grant date. 25% of the option shares will vest and become exercisable on 01/02/2027, with the remaining shares vesting in 36 equal monthly installments over the following three years, so full vesting occurs over four years. After this grant, Kordasiewicz beneficially owned 16,600 stock options in total, held directly.